Information  X 
Enter a valid email address

Astrazeneca PLC OrdShs USD0.25 (AZN)

Date Time Source Announcement
26 Mar 2020 7:00 am
RNS
Lokelma approved in Japan for hyperkalaemia
  7:00 am
RNS
Director/PDMR Shareholding
24 Mar 2020 4:41 pm
RNS
Second Price Monitoring Extn
  4:36 pm
RNS
Price Monitoring Extension
  12:02 pm
RNS
Price Monitoring Extension
23 Mar 2020 4:40 pm
RNS
Second Price Monitoring Extn
  4:36 pm
RNS
Price Monitoring Extension
  12:08 pm
RNS
Second Price Monitoring Extn
  12:03 pm
RNS
Price Monitoring Extension
20 Mar 2020 10:20 am
RNS
Second Price Monitoring Extn
  10:15 am
RNS
Price Monitoring Extension
  7:00 am
RNS
Director/PDMR Shareholding
19 Mar 2020 7:00 am
RNS
Lynparza granted orphan drug designation in Japan
17 Mar 2020 7:00 am
RNS
Imfinzi confirmed overall survival in CASPIAN
13 Mar 2020 4:35 pm
RNS
Price Monitoring Extension
12 Mar 2020 11:00 am
RNS
Notice of AGM
  7:00 am
RNS
Update on Phase III GY004 trial for cediranib
10 Mar 2020 7:00 am
RNS
Director/PDMR Shareholding
06 Mar 2020 7:00 am
RNS
Update on Phase III DANUBE trial in bladder cancer
04 Mar 2020 7:00 am
RNS
Filing of Form 20-F with SEC
03 Mar 2020 11:00 am
RNS
Annual Financial Report
02 Mar 2020 3:00 pm
RNS
Total Voting Rights
  7:00 am
RNS
Divestment of hypertension medicines completed
27 Feb 2020 7:00 am
RNS
Director/PDMR Shareholding
25 Feb 2020 7:00 am
RNS
AstraZeneca divests global rights to Movantik
19 Feb 2020 7:00 am
RNS
Director/PDMR Shareholding
14 Feb 2020 7:00 am
RNS
AZN: Full-year and Q4 2019 results
03 Feb 2020 3:00 pm
RNS
Total Voting Rights
27 Jan 2020 7:00 am
RNS
Enhertu Phase II trial met primary endpoint
  7:00 am
RNS
Brilinta met primary endpoint in stroke trial
  7:00 am
RNS
AstraZeneca divests hypertension medicines
  7:00 am
RNS
AstraZeneca to recover brazikumab (MEDI2070)
20 Jan 2020 7:00 am
RNS
Imfinzi, tremelimumab granted ODD in liver cancer
  7:00 am
RNS
FDA grants Lynparza Priority Review for PROfound
13 Jan 2020 7:01 am
RNS
Lynparza granted FDA Priority Review for PAOLA-1
  7:00 am
RNS
Update on Epanova Phase III STRENGTH trial
06 Jan 2020 7:01 am
RNS
Farxiga granted FDA heart failure Priority Review
  7:00 am
RNS
Lokelma approved in China for hyperkalaemia
02 Jan 2020 3:00 pm
RNS
Total Voting Rights
30 Dec 2019 7:00 am
RNS
US FDA approved Lynparza for pancreatic cancer
23 Dec 2019 7:00 am
RNS
Triple-combination approved in China for COPD
  7:00 am
RNS
Enhertu (trastuzumab deruxtecan) approved in US
20 Dec 2019 7:00 am
RNS
AstraZeneca divests rights to Arimidex and Casodex
17 Dec 2019 6:06 pm
RNS
FDA panel backs Lynparza use for pancreatic cancer
16 Dec 2019 7:00 am
RNS
Seroquel rights agreement complete: Europe, Russia
12 Dec 2019 7:00 am
RNS
Imfinzi approved in China for Stage III NSCLC
11 Dec 2019 1:00 pm
RNS
Trastuzumab deruxtecan achieves ORR of 60.9%
05 Dec 2019 7:00 am
RNS
Lynparza approved in China for 1L BRCAm ovarian
03 Dec 2019 7:00 am
RNS
AstraZeneca divests Seroquel rights: US and Canada
02 Dec 2019 3:00 pm
RNS
Block listing Interim Review
  3:00 pm
RNS
Total Voting Rights
29 Nov 2019 7:00 am
RNS
Imfinzi granted FDA Priority Review for SCLC
21 Nov 2019 6:15 pm
RNS
Calquence approved in CLL in the US
15 Nov 2019 7:00 am
RNS
Qtrilmet approved in the EU for treatment of T2D
14 Nov 2019 7:00 am
RNS
FDA accepts regulatory submission for selumetinib
12 Nov 2019 7:00 am
RNS
Anifrolumab demonstrated superiority in TULIP 2
11 Nov 2019 7:00 am
RNS
Roxadustat pooled analyses: no increased CV risk
08 Nov 2019 7:00 am
RNS
Roxadustat significantly increased haemoglobin
06 Nov 2019 2:10 pm
RNS
Calquence data to show improved progression-free
 
Headlines
Top categories

27-Mar-2020 04:50 PM

Broker Forecast - Berenberg issues a broker note on Marston's PLC

Berenberg today reaffirms its hold investment rating on Marston's PLC (LON:MARS) and cut its price target to 50p (from 110p). Story provided by Stock ...

Company finder
Forthcoming announcements

a d v e r t i s e m e n t